26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021
IMO Kazia management will wait for the final data from paxalisib phase2 Kazia / Danna-Farber GBM trial results, and then submit a New Drug Application (NDA) submission, which may result in a faster product approval for paxalisib.
Regards.
- Forums
- ASX - By Stock
- KZA
- SNO 26th Annual Meeting
SNO 26th Annual Meeting, page-2
-
- There are more pages in this discussion • 122 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)